SQI Closes $3.8M Private Placement | GenomeWeb

NEW YORK (GenomeWeb News) – SQI today said it has raised almost C$3.85 million (US$3.81 million) in a non-brokered private placement of its stock.

The Toronto-based microarray-based diagnostics firm placed more than 5.1 million units at C$.75 per unit. Each unit consists of one common share and one common share purchase warrant. Each warrant entitles the holder to purchase one common share at C$1.10 for up to two years after the date of issuance.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CBC Marketplace commissions DNA testing of chicken sandwiches at Subway and other fast-food chains.

In a speech to Congress, President Donald Trump called the drug approval process at FDA "slow and burdensome."

In Genome Research this week: algorithm to tease out strains from metagenomic sequences, drug resistance mechanisms in cancer cells, and more.

Variants in the IFITM3 gene affect inflammatory response to infection, UPI reports.